15 results
10-K
2023 FY
EX-10.12
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
, BioNTech has the sole right to determine whether and how to implement a recall or other market withdrawal of a [***] Licensed Product in the Field
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
, manufacturer, or holder of an approved BLA, including, among other things, recall or withdrawal of the product from the market.
The FDA also may require post … obtain marketing approval could be subject to post-marketing restrictions or recall or withdrawal from the market, and we may be subject to penalties
6-K
EX-1
AUTL
Autolus Therapeutics plc
30 Jun 21
Annual Report and Accounts
6:05am
obtain marketing approval could be subject to post-marketing restrictions or recall or withdrawal from the market, and we may be subject to penalties … pending applications or supplements to approved applications that we submit;
recall of products;
fines, restitution or disgorgement of profits
6-K
EX-1
zebnpbuejtprn zk4gj
26 May 20
Current report (foreign)
4:31pm
6-K
EX-1
wzaa0st5 09
15 Mar 19
Annual Report and Accounts
5:26pm
20-F
lfqpu0as
23 Nov 18
Annual report (foreign)
12:00am
424B4
yy6oz31wxq5 pp
22 Jun 18
Prospectus supplement with pricing info
4:02pm
F-1/A
5oath4jz039aby
19 Jun 18
Registration statement (foreign) (amended)
8:05am
F-1/A
nv3ipjfx7p2 f7mcrd
8 Jun 18
Registration statement (foreign) (amended)
6:25am
F-1/A
xch b3by8m2fgx
10 May 18
Registration statement (foreign) (amended)
5:19pm
F-1
dn2hi br3xb
7 May 18
Registration statement (foreign)
4:45pm
- Prev
- 1
- Next